CoII/Box‐catalyzed [Box=bis(oxazoline)] enantioselective addition of potassium allyltrifluoroborate to cyclic ketimines was developed, providing the corresponding chiral α‐tertiary amines in high yields and with good enantioselectivity values. Alkoxycarbonyl‐ and alkyl‐substituted saccharin‐derived ketimines are suitable substrates for this allylation reaction. The product can be converted to complex molecules
开发了Co II / Box催化的[Box =双(恶唑啉)]烯丙基三氟硼酸钾对环酮亚胺的对映选择性加成,提供了高收率和良好对映选择性值的相应手性α-叔胺。烷氧羰基和烷基取代的糖精衍生的酮亚胺是该烯丙基化反应的合适底物。该产品可以通过几个简单的步骤转化为复杂的分子,包括MK-0371的前体,它是一种驱动蛋白纺锤体蛋白抑制剂。另外,该催化体系显示出强烈的正非线性效应。
Copper-catalyzed asymmetric alkynylation of cyclic N-sulfonyl ketimines
cyclic N-sulfonyl ketimines was developed, providing the corresponding chiral α-tertiary amines with up to 98% ee. The method tolerates some variations in cyclic N-sulfonyl ketimine and alkyne scope. These products could be used in several transformations, in particular, the products of 6-membered cyclic N-sulfonyl ketimines could be easily converted to linear chiral α-tertiary amines. This asymmetric
SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE
申请人:Dolle Roland E.
公开号:US20100029614A1
公开(公告)日:2010-02-04
Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.
Methods for enhancing cognitive function are disclosed. More particularly, methods are disclosed for enhancing cognitive function comprising the step of administering spirocyclic heterocyclic derivatives (including derivatives of spiro(2H-1-benzopyran-2,4′-piperidines) of the general formula IV:
UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS
申请人:ALLEN Jennifer R.
公开号:US20110306587A1
公开(公告)日:2011-12-15
Unsaturated nitrogen heterocyclic compounds of formula (I):
as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.